Description of a Novel Multiplex Avidity Assay for Evaluating HPV Antibodies

Overview

Journal J Immunol Methods

Publisher Elsevier

Specialties Allergy & Immunology
Pathology

Date 2017 Apr 24

PMID 28433580

Citations 7

Authors

Allison M Brady

Elizabeth R Unger

Gitika Panicker

Affiliations

Soon will be listed here.

Abstract

Limited data exists regarding antibody avidity for human papillomavirus (HPV). We describe development of a multiplex electrochemiluminescent avidity ELISA for four HPV types (HPV 6, 11, 16, 18) by adding a dissociating step to our established multiplex HPV VLP ELISA. Initial experiments exploring ammonium thiocyanate, sodium thiocyanate and guanidine hydrochloride (GuHCl) as dissociating agents identified GuHCl as most promising. Dissociation conditions with GuHCl were varied (concentration, incubation time, temperature) to select conditions with minimal impact on VLP integrity as measured with monoclonal antibodies to conformational epitopes. Avidity index (AI) was calculated based on a standard curve as ratio of bound IgG in GuHCl treated versus untreated sample. To evaluate our assay we determined AI in sera with known HPV titers. We selected 32 residual anonymized sera from individuals with a wide range of titers for HPV6, 11, 16, and 18. AIs were similar across multiple dilutions of serum within the assay's dynamic range and were reproducible with two plate lots. This assay will aid in understanding HPV antibody avidity and maturation in response to natural infection and varying vaccine schedules. This is the first report of a VLP-based multiplexed avidity ELISA that evaluates assay parameters for all nine HPV vaccine types.

Citing Articles

Microarray-Based Avidity Assay for Assessment of Thyroid Autoantibodies.

Savvateeva E, Sokolova V, Yukina M, Nuralieva N, Kulagina E, Donnikov M Diagnostics (Basel). 2025; 15(3).

PMID: 39941271 PMC: 11817500. DOI: 10.3390/diagnostics15030341.

Antibody Avidity Maturation Following Booster Vaccination with an Intranasal Adenovirus Salnavac Vaccine.

Astakhova E, Baranov K, Shilova N, Polyakova S, Zuev E, Poteryaev D Vaccines (Basel). 2025; 12(12.

PMID: 39772024 PMC: 11680177. DOI: 10.3390/vaccines12121362.

The quantity and quality of anti-SARS-CoV-2 antibodies show contrariwise association with COVID-19 severity: lessons learned from IgG avidity.

Hajilooi M, Keramat F, Moazenian A, Rastegari-Pouyani M, Solgi G Med Microbiol Immunol. 2023; 212(3):203-220.

PMID: 37103583 PMC: 10133916. DOI: 10.1007/s00430-023-00763-y.

Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.

Dapporto F, Marchi S, Leonardi M, Piu P, Lovreglio P, Decaro N J Immunol Res. 2022; 2022:4813199.

PMID: 36093434 PMC: 9453088. DOI: 10.1155/2022/4813199.

Modified ELISA for antibody avidity evaluation: The need for standardization.

Araujo Correa V, Rodrigues T, Portilho A, Trzewikoswki de Lima G, De Gaspari E Biomed J. 2021; 44(4):433-438.

PMID: 34493482 PMC: 8515003. DOI: 10.1016/j.bj.2020.10.009.

References

Anttila M, Voutilainen M, Jantti V, Eskola J, Kayhty H . Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin Exp Immunol. 1999; 118(3):402-7. PMC: 1905437. DOI: 10.1046/j.1365-2249.1999.01077.x. View

Schlesinger Y, Granoff D . Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA. 1992; 267(11):1489-94. View

Rizk R, Christensen N, Michael K, Muller M, Sehr P, Waterboer T . Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol. 2007; 89(Pt 1):117-129. DOI: 10.1099/vir.0.83145-0. View

Buck C, Thompson C . Production of papillomavirus-based gene transfer vectors. Curr Protoc Cell Biol. 2008; Chapter 26:Unit 26.1. DOI: 10.1002/0471143030.cb2601s37. View

Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J . Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2008; 15(1):34-41. PMC: 2987729. DOI: 10.1038/nm.1894. View

Victora G, Nussenzweig M . Germinal centers. Annu Rev Immunol. 2012; 30:429-57. DOI: 10.1146/annurev-immunol-020711-075032. View

Dauner J, Pan Y, Hildesheim A, Kemp T, Porras C, Pinto L . Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals. Mol Cell Probes. 2012; 26(2):73-80. PMC: 3319198. DOI: 10.1016/j.mcp.2012.01.002. View

Licciardi P, Balloch A, Russell F, Burton R, Lin J, Nahm M . Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses. J Allergy Clin Immunol. 2012; 129(3):794-800.e2. PMC: 3318993. DOI: 10.1016/j.jaci.2011.11.043. View

Almanzar G, Ottensmeier B, Liese J, Prelog M . Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate. J Immunol Methods. 2012; 387(1-2):36-42. DOI: 10.1016/j.jim.2012.09.008. View

10.

Kemp T, Safaeian M, Hildesheim A, Pan Y, Penrose K, Porras C . Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix(®). Vaccine. 2012; 31(1):165-70. PMC: 3527627. DOI: 10.1016/j.vaccine.2012.10.067. View

11.

Scherpenisse M, Schepp R, Mollers M, Meijer C, Berbers G, van der Klis F . Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLoS One. 2013; 8(9):e74797. PMC: 3776846. DOI: 10.1371/journal.pone.0074797. View

12.

Boxus M, Lockman L, Fochesato M, Lorin C, Thomas F, Giannini S . Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine. 2014; 32(26):3232-6. DOI: 10.1016/j.vaccine.2014.04.005. View

13.

Herrin D, Coates E, Costner P, Kemp T, Nason M, Saharia K . Comparison of adaptive and innate immune responses induced by licensed vaccines for Human Papillomavirus. Hum Vaccin Immunother. 2014; 10(12):3446-54. PMC: 4514049. DOI: 10.4161/hv.34408. View

14.

Einstein M, Takacs P, Chatterjee A, Sperling R, Chakhtoura N, Blatter M . Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a Phase III randomized trial. Hum Vaccin Immunother. 2014; 10(12):3435-45. PMC: 4514070. DOI: 10.4161/hv.36121. View

15.

Panicker G, Rajbhandari I, Gurbaxani B, Querec T, Unger E . Development and evaluation of multiplexed immunoassay for detection of antibodies to HPV vaccine types. J Immunol Methods. 2015; 417:107-114. PMC: 4587388. DOI: 10.1016/j.jim.2014.12.013. View

16.

Petrosky E, Bocchini Jr J, Hariri S, Chesson H, Curtis C, Saraiya M . Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015; 64(11):300-4. PMC: 4584883. View

17.

Castle P, Maza M . Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2015; 144(3):449-68. DOI: 10.1017/S0950268815002198. View

18.

Sankaranarayanan R, Prabhu P, Pawlita M, Gheit T, Bhatla N, Muwonge R . Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol. 2015; 17(1):67-77. PMC: 5357737. DOI: 10.1016/S1470-2045(15)00414-3. View

19.

Christensen N, Kirnbauer R, Schiller J, Ghim S, Schlegel R, Jenson A . Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology. 1994; 205(1):329-35. DOI: 10.1006/viro.1994.1649. View

20.

Granoff D, Lucas A . Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann N Y Acad Sci. 1995; 754:278-88. DOI: 10.1111/j.1749-6632.1995.tb44461.x. View